Analyst Price Targets — CDMO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 30, 2024 6:28 am | Sean Dodge | RBC Capital | $8.00 | $7.56 | StreetInsider | Avid Bioservices (CDMO) PT Raised to $8 at RBC Capital |
Latest News for CDMO
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the…
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK SitePR NewswireMUMBAI, India, Sept. 16, 2026Piramal Phar
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Samsung Biologics publishes prospectus for PolyPeptide public tender offer PR Newswire INCHEON, South Korea and ZU
4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufactu
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CDMO.
U.S. House Trading
No House trades found for CDMO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.